Tadalafil

Tadalafil's primary mechanism is selective inhibition of phosphodiesterase type 5 (PDE5), one of eleven mammalian PDE isoforms. PDE5 is a cGMP-specific phosphodiesterase that hydrolyzes cGMP — the second messenger generated downstream of nitric oxide (NO) signaling — into inactive 5'-GMP. By inhibiting PDE5, tadalafil preserves cGMP accumulation in cells where NO-cGMP signaling is active, prolonging and amplifying the functional consequences of this signaling. The NO-cGMP pathway in vascular smooth muscle (the context where PDE5 inhibitor effects are most clinically relevant) works as follows: endothelial nitric oxide synthase (eNOS) in vascular endothelium produces NO in response to shear stress, acetylcholine, bradykinin, and sexual stimulation (in penile tissue); NO diffuses from endothelium into adjacent vascular smooth muscle cells; NO activates soluble guanylate cyclase (sGC), which converts GTP to cGMP; cGMP activates protein kinase G (PKG), which phosphorylates multiple targets including myosin light chain phosphatase (promoting actin-myosin dissociation and smooth muscle relaxation), IP3 receptors (reducing intracellular calcium release), and sarcoplasmic reticulum calcium ATPase (promoting calcium sequestration). The net effect is vascular smooth muscle relaxation, vasodilation, and increased blood flow. PDE5 normally counterbalances this pathway by degrading cGMP, ensuring signaling terminates when NO stimulus decreases. PDE5 inhibition by tadalafil (or sildenafil, vardenafil, avanafil) tips the balance toward cGMP accumulation, improving and prolonging vasodilation wherever PDE5 and the NO-cGMP pathway are active. Tissue distribution of PDE5 determines where tadalafil produces meaningful effects: Corpus cavernosum of the penis: High PDE5 expression; tadalafil produces strong pro-erectile effects via smooth muscle relaxation, corporal sinusoid expansion, and trabecular relaxation, coupled with venous occlusion (the erectile mechanism). This is the primary FDA-approved indication. Pulmonary vasculature: Substantial PDE5 expression; tadalafil produces pulmonary vasodilation, reducing pulmonary arterial pressure and right ventricular workload. This is the basis for PAH approval at higher doses. Bladder and prostate: PDE5 expression in bladder detrusor, bladder neck, prostate stromal smooth muscle, and prostate urethra. Tadalafil's effects on these tissues reduce bladder outlet resistance, improve bladder storage and emptying function, and reduce BPH/LUTS symptoms. This is the basis for BPH/LUTS approval. Systemic vasculature: Lower PDE5 expression than pulmonary or penile circulation, but sufficient for modest systemic blood pressure reduction (typically 2-6 mmHg systolic at standard doses). Cerebral vasculature: Emerging research on cerebrovascular effects; possible contribution to cognitive/Alzheimer's signal from observational data. Skeletal muscle vasculature: Modest effects on exercise-induced vasodilation; possible ergogenic implications (detected by WADA; tadalafil is not on the prohibited list but has been investigated for performance benefits). Cardiac tissue: Some PDE5 expression in cardiomyocytes; emerging research on cardiac remodeling, heart failure with preserved ejection fraction, and diabetic cardiomyopathy. Selectivity profile: Tadalafil is highly selective for PDE5 versus most other PDE isoforms. It is approximately 10,000-fold more potent against PDE5 than PDE2, PDE3, or PDE4, and approximately 10,000-fold more potent against PDE5 than PDE1, PDE7, PDE8, PDE9, or PDE10. Notably, tadalafil has somewhat higher affinity for PDE11 than sildenafil or vardenafil — PDE11 is expressed in skeletal muscle, prostate, pituitary, and testis — which may contribute to tadalafil's distinct side-effect profile (back pain and muscle pain are more common with tadalafil than with other PDE5 inhibitors, possibly related to PDE11 inhibition in skeletal muscle). Tadalafil does not significantly inhibit PDE6 (which is expressed in retinal photoreceptors), explaining why tadalafil does not produce the blue-tinted vision or color perception disturbances that occasionally occur with sildenafil. Pharmacokinetics: Oral tadalafil is well-absorbed with oral bioavailability of approximately 65%. Peak plasma concentrations are reached at 2-4 hours post-dose (slower than sildenafil's 30-60 minute peak); food does not significantly affect absorption. Plasma half-life is approximately 17-18 hours, giving an effective duration of action of approximately 36 hours (versus sildenafil ~4-6 hours). This long half-life reflects tadalafil's slow metabolism and renal/fecal elimination. Metabolism: Tadalafil is extensively metabolized by CYP3A4, with minor contributions from CYP2C9. The major metabolite, catechol-tadalafil, is pharmacologically inactive. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice) substantially elevate tadalafil exposure — 1,400-fold AUC increase with ketoconazole — requiring dose adjustment (maximum 10 mg every 72 hours when on strong CYP3A4 inhibitors). Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort) substantially reduce tadalafil exposure. Elimination: Primarily fecal (61%) with smaller renal component (36%). Steady state is reached after approximately 5 days of once-daily dosing. Beyond the direct PDE5 mechanism, tadalafil produces several downstream effects with potential clinical relevance: Enhanced endothelial function: Consistent improvement in flow-mediated dilation (FMD), a marker of endothelial function. Mechanism involves cGMP-mediated eNOS upregulation, improved NO bioavailability, reduced oxidative stress in endothelium, and cGMP-PKG effects on endothelial integrity. Antioxidant and anti-inflammatory effects: cGMP-PKG signaling reduces reactive oxygen species generation and NF-κB-mediated inflammatory signaling. These effects may underlie some of the emerging cardiovascular and neuroprotective benefits. Mitochondrial effects: cGMP-PKG signaling influences mitochondrial biogenesis (via PGC-1α), mitophagy, and mitochondrial respiratory efficiency. Tadalafil has been shown to preserve mitochondrial function in various pathologic models. Smooth muscle effects in non-vascular tissue: PDE5 expression in airway smooth muscle (modest bronchodilation, though PDE4 inhibition is more clinically relevant for asthma/COPD), uterine smooth muscle, and gastrointestinal smooth muscle contributes to some less-common effects. Possible neuroprotective effects: cGMP-PKG signaling in neurons influences long-term potentiation, synaptic plasticity, and neuroprotective gene expression. The observational Fang 2024 Alzheimer's signal may reflect these mechanisms, though causation is unestablished.

Tadalafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), an enzyme that hydrolyzes cyclic guanosine monophosphate (cGMP) into non-cyclic 5'-GMP. By inhibiting PDE5, tadalafil preserves cGMP signaling in tissues where PDE5 is expressed — principally vascular smooth muscle of the corpus cavernosum, pulmonary vasculature, prostate, bladder, and to varying degrees other vascular beds — producing smooth muscle relaxation, enhanced blood flow, and tissue-specific functional effects. Tadalafil was developed by Lilly/ICOS and first approved by the FDA in November 2003 for erectile dysfunction (ED), joining sildenafil (Viagra, approved 1998) and vardenafil (Levitra, approved 2003) in the PDE5 inhibitor class. Tadalafil's distinguishing pharmacokinetic feature is its very long half-life of approximately 17-18 hours (versus sildenafil's ~4 hours), producing a clinical duration of action of up to 36 hours — hence the nickname "the weekend pill." This long duration allows greater flexibility in dosing-to-activity timing and has driven tadalafil's commercial success in competition with shorter-acting PDE5 inhibitors. Tadalafil was subsequently approved for additional indications based on its PDE5 inhibition in other tissues: pulmonary arterial hypertension (PAH) in 2009 under the brand name Adcirca at higher dose (40 mg once daily, later revised to 20 mg twice daily formulation), based on the PHIRST trial (Galiè et al. 2009); benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS) in 2011, based on trials demonstrating improvements in International Prostate Symptom Score (IPSS) in men with and without concurrent ED (Oelke et al. 2012). The long half-life made tadalafil uniquely suited to once-daily dosing for BPH and for chronic low-dose ED management, leading to approval of a 2.5 mg and 5 mg once-daily formulation for continuous use in 2008 — a regimen now widely adopted for men seeking predictable sexual function without event-specific dosing as well as BPH symptom management. Tadalafil's generic patent expired in late 2018 in the United States, dramatically reducing cost from approximately $15-35 per pill (brand) to $1-5 per pill (generic) and driving substantial expansion of prescribing. Off-label and emerging applications have grown significantly: endothelial function support in patients with vascular risk factors, based on consistent evidence that PDE5 inhibition improves flow-mediated dilation and other endothelial function markers; potential cardiovascular benefit beyond ED, with ongoing research into heart failure with preserved ejection fraction, diabetic microvascular disease, and post-myocardial infarction recovery; possible cognitive/neuroprotective effects, triggered by observational data (Fang et al. 2024 showing 30-69% reduced Alzheimer's risk in men with BPH prescribed PDE5 inhibitors for >5 years) though causation is unproven; emerging longevity interest based on endothelial, mitochondrial, and NO/cGMP-pathway effects; and Raynaud's phenomenon, altitude sickness (off-label, related to pulmonary vasodilation), and female sexual dysfunction (mixed results, not FDA approved). Tadalafil sits at the intersection of several distinct patient populations: middle-aged and older men with ED (the majority use case); men with BPH/LUTS with or without ED (particularly well-suited given single-drug coverage of both issues); patients with pulmonary arterial hypertension (a serious condition with limited treatment options); and a growing population using low-dose daily tadalafil off-label for longevity, endothelial health, or enhanced sexual function in the absence of formal ED diagnosis. This broad and expanding use profile, combined with the substantial cost reduction from generic availability, has made tadalafil one of the most-prescribed medications in middle-aged men globally. The safety profile is well-characterized from decades of use and millions of person-years of exposure. Common side effects (headache, flushing, dyspepsia, back pain, nasal congestion) are typically mild and transient. The serious safety concerns — nitrate interaction producing life-threatening hypotension, and priapism — are well-understood and manageable with appropriate prescribing. The interaction profile is substantial, particularly with nitrates (absolute contraindication) and alpha-blockers (relative; requires dose separation and caution). CYP3A4-mediated drug interactions affect tadalafil's pharmacokinetics and must be considered in patients taking strong CYP3A4 inhibitors or inducers. This entry covers tadalafil's mechanism (PDE5 inhibition, NO/cGMP pathway, tissue-selective effects); FDA-approved indications (ED, BPH/LUTS, PAH); off-label and emerging applications (endothelial health, cognitive effects, cardiovascular adjunct uses); dosing strategies (event-specific versus daily, dose titration); the safety profile and critical interactions; and appropriate integration into male health, cardiovascular, and longevity protocols. Tadalafil is distinct from its research-chemical analog aminotadalafil — which lacks FDA approval, has inconsistent quality control, and carries the regulatory risk of gray-market sourcing. Cross-pathway integration with related interventions including NMN, metformin, and berberine is discussed.

IUPAC Name

Not yet available

CAS Number

Not yet available

Molecular Formula

Not yet available

Molecular Mass

Not yet available

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Get Tadalafil Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Sign in to set alerts

Related Compounds

View All

Data Completeness

63%

Research Credibility